Risk of hyperkalemia associated with selective COX-2 inhibitors

Hisham Aljadhey, Wanzhu Tu, Richard A. Hansen, Susan Blalock, D. Craig Brater, Michael Murray

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: Selective cyclooxygenase-2 (COX-2) inhibitors have been linked to cardiac death. The mechanism for this adverse effect appears to be by ischemic insult; however another mechanism could involve hyperkalemia. The objective of this study was to determine the effects of selective COX-2 inhibitors and non-selective nonsteroidal anti-inflammatory drugs (NSAIDs) on serum potassium concentration and the electrocardiogram. Methods: A retrospective cohort study was conducted using propensity score matching of patients from an inner-city academic medical center at Indianapolis, Indiana. Two hundred and two patients prescribed selective COX-2 inhibitors were matched to 202 patients prescribed non-selective NSAIDs using propensity scores methods. Outcomes included change in serum potassium concentration from baseline and the risk of an abnormal electrocardiogram. Results: Compared to patients prescribed non-selective NSAIDs, those prescribed a selective COX-2 inhibitor had a higher risk of serum potassium increase greater than 5 mEq/L (OR, 2.56; 95%CI, 1.03-6.36). However, patients prescribed selective COX-2 inhibitors had no greater risk of electrocardiogram abnormality (OR, 1.16; 95%CI, 0.74-1.82). Conclusions: Selective COX-2 inhibitors may have a greater risk of hyperkalemia than non-selective NSAIDs. This study was exploratory with small numbers of patients. Further studies are needed to confirm these results and any association with cardiovascular events.

Original languageEnglish
Pages (from-to)1194-1198
Number of pages5
JournalPharmacoepidemiology and Drug Safety
Volume19
Issue number11
DOIs
StatePublished - Nov 2010

Fingerprint

Hyperkalemia
Cyclooxygenase 2 Inhibitors
Anti-Inflammatory Agents
Propensity Score
Potassium
Electrocardiography
Pharmaceutical Preparations
Serum
Cohort Studies
Retrospective Studies

Keywords

  • Hyperkalemia
  • NSAIDs
  • Retrospective cohort study, propensity score
  • Selective COX-2 inhibitors

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Epidemiology

Cite this

Risk of hyperkalemia associated with selective COX-2 inhibitors. / Aljadhey, Hisham; Tu, Wanzhu; Hansen, Richard A.; Blalock, Susan; Brater, D. Craig; Murray, Michael.

In: Pharmacoepidemiology and Drug Safety, Vol. 19, No. 11, 11.2010, p. 1194-1198.

Research output: Contribution to journalArticle

Aljadhey, Hisham ; Tu, Wanzhu ; Hansen, Richard A. ; Blalock, Susan ; Brater, D. Craig ; Murray, Michael. / Risk of hyperkalemia associated with selective COX-2 inhibitors. In: Pharmacoepidemiology and Drug Safety. 2010 ; Vol. 19, No. 11. pp. 1194-1198.
@article{d2ba6808585548a9a00a5c192b72e2fd,
title = "Risk of hyperkalemia associated with selective COX-2 inhibitors",
abstract = "Background: Selective cyclooxygenase-2 (COX-2) inhibitors have been linked to cardiac death. The mechanism for this adverse effect appears to be by ischemic insult; however another mechanism could involve hyperkalemia. The objective of this study was to determine the effects of selective COX-2 inhibitors and non-selective nonsteroidal anti-inflammatory drugs (NSAIDs) on serum potassium concentration and the electrocardiogram. Methods: A retrospective cohort study was conducted using propensity score matching of patients from an inner-city academic medical center at Indianapolis, Indiana. Two hundred and two patients prescribed selective COX-2 inhibitors were matched to 202 patients prescribed non-selective NSAIDs using propensity scores methods. Outcomes included change in serum potassium concentration from baseline and the risk of an abnormal electrocardiogram. Results: Compared to patients prescribed non-selective NSAIDs, those prescribed a selective COX-2 inhibitor had a higher risk of serum potassium increase greater than 5 mEq/L (OR, 2.56; 95{\%}CI, 1.03-6.36). However, patients prescribed selective COX-2 inhibitors had no greater risk of electrocardiogram abnormality (OR, 1.16; 95{\%}CI, 0.74-1.82). Conclusions: Selective COX-2 inhibitors may have a greater risk of hyperkalemia than non-selective NSAIDs. This study was exploratory with small numbers of patients. Further studies are needed to confirm these results and any association with cardiovascular events.",
keywords = "Hyperkalemia, NSAIDs, Retrospective cohort study, propensity score, Selective COX-2 inhibitors",
author = "Hisham Aljadhey and Wanzhu Tu and Hansen, {Richard A.} and Susan Blalock and Brater, {D. Craig} and Michael Murray",
year = "2010",
month = "11",
doi = "10.1002/pds.2011",
language = "English",
volume = "19",
pages = "1194--1198",
journal = "Pharmacoepidemiology and Drug Safety",
issn = "1053-8569",
publisher = "John Wiley and Sons Ltd",
number = "11",

}

TY - JOUR

T1 - Risk of hyperkalemia associated with selective COX-2 inhibitors

AU - Aljadhey, Hisham

AU - Tu, Wanzhu

AU - Hansen, Richard A.

AU - Blalock, Susan

AU - Brater, D. Craig

AU - Murray, Michael

PY - 2010/11

Y1 - 2010/11

N2 - Background: Selective cyclooxygenase-2 (COX-2) inhibitors have been linked to cardiac death. The mechanism for this adverse effect appears to be by ischemic insult; however another mechanism could involve hyperkalemia. The objective of this study was to determine the effects of selective COX-2 inhibitors and non-selective nonsteroidal anti-inflammatory drugs (NSAIDs) on serum potassium concentration and the electrocardiogram. Methods: A retrospective cohort study was conducted using propensity score matching of patients from an inner-city academic medical center at Indianapolis, Indiana. Two hundred and two patients prescribed selective COX-2 inhibitors were matched to 202 patients prescribed non-selective NSAIDs using propensity scores methods. Outcomes included change in serum potassium concentration from baseline and the risk of an abnormal electrocardiogram. Results: Compared to patients prescribed non-selective NSAIDs, those prescribed a selective COX-2 inhibitor had a higher risk of serum potassium increase greater than 5 mEq/L (OR, 2.56; 95%CI, 1.03-6.36). However, patients prescribed selective COX-2 inhibitors had no greater risk of electrocardiogram abnormality (OR, 1.16; 95%CI, 0.74-1.82). Conclusions: Selective COX-2 inhibitors may have a greater risk of hyperkalemia than non-selective NSAIDs. This study was exploratory with small numbers of patients. Further studies are needed to confirm these results and any association with cardiovascular events.

AB - Background: Selective cyclooxygenase-2 (COX-2) inhibitors have been linked to cardiac death. The mechanism for this adverse effect appears to be by ischemic insult; however another mechanism could involve hyperkalemia. The objective of this study was to determine the effects of selective COX-2 inhibitors and non-selective nonsteroidal anti-inflammatory drugs (NSAIDs) on serum potassium concentration and the electrocardiogram. Methods: A retrospective cohort study was conducted using propensity score matching of patients from an inner-city academic medical center at Indianapolis, Indiana. Two hundred and two patients prescribed selective COX-2 inhibitors were matched to 202 patients prescribed non-selective NSAIDs using propensity scores methods. Outcomes included change in serum potassium concentration from baseline and the risk of an abnormal electrocardiogram. Results: Compared to patients prescribed non-selective NSAIDs, those prescribed a selective COX-2 inhibitor had a higher risk of serum potassium increase greater than 5 mEq/L (OR, 2.56; 95%CI, 1.03-6.36). However, patients prescribed selective COX-2 inhibitors had no greater risk of electrocardiogram abnormality (OR, 1.16; 95%CI, 0.74-1.82). Conclusions: Selective COX-2 inhibitors may have a greater risk of hyperkalemia than non-selective NSAIDs. This study was exploratory with small numbers of patients. Further studies are needed to confirm these results and any association with cardiovascular events.

KW - Hyperkalemia

KW - NSAIDs

KW - Retrospective cohort study, propensity score

KW - Selective COX-2 inhibitors

UR - http://www.scopus.com/inward/record.url?scp=78049308961&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78049308961&partnerID=8YFLogxK

U2 - 10.1002/pds.2011

DO - 10.1002/pds.2011

M3 - Article

C2 - 20842761

AN - SCOPUS:78049308961

VL - 19

SP - 1194

EP - 1198

JO - Pharmacoepidemiology and Drug Safety

JF - Pharmacoepidemiology and Drug Safety

SN - 1053-8569

IS - 11

ER -